

Allan Hildesheim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7303721/publications.pdf>

Version: 2024-02-01

309
papers

21,736
citations

6606

79
h-index

11601

135
g-index

310
all docs

310
docs citations

310
times ranked

17147
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 743.	3.8	581
2	Population-Based Study of Human Papillomavirus Infection and Cervical Neoplasia in Rural Costa Rica. <i>Journal of the National Cancer Institute</i> , 2000, 92, 464-474.	3.0	515
3	The carcinogenicity of human papillomavirus types reflects viral evolution. <i>Virology</i> , 2005, 337, 76-84.	1.1	487
4	HPV DNA Testing in Cervical Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 87.	3.8	466
5	Rapid Clearance of Human Papillomavirus and Implications for Clinical Focus on Persistent Infections. <i>Journal of the National Cancer Institute</i> , 2008, 100, 513-517.	3.0	436
6	Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica. <i>PLoS ONE</i> , 2013, 8, e68329.	1.1	387
7	MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 5874-5878.	3.3	385
8	Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. <i>Cancer</i> , 2004, 100, 1035-1044.	2.0	367
9	A Prospective Study of Age Trends in Cervical Human Papillomavirus Acquisition and Persistence in Guanacaste, Costa Rica. <i>Journal of Infectious Diseases</i> , 2005, 191, 1808-1816.	1.9	354
10	Epidemiologic Profile of Type-specific Human Papillomavirus Infection and Cervical Neoplasia in Guanacaste, Costa Rica. <i>Journal of Infectious Diseases</i> , 2005, 191, 1796-1807.	1.9	322
11	Longitudinal Study of Human Papillomavirus Persistence and Cervical Intraepithelial Neoplasia Grade 2/3: Critical Role of Duration of Infection. <i>Journal of the National Cancer Institute</i> , 2010, 102, 315-324.	3.0	320
12	Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 2708-2715.	0.8	280
13	Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1444-1451.	3.0	274
14	Host and viral genetics and risk of cervical cancer: a review. <i>Virus Research</i> , 2002, 89, 229-240.	1.1	270
15	An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. <i>Vaccine</i> , 2008, 26, K53-K61.	1.7	266
16	Cigarette Smoking and Variations in Systemic Immune and Inflammation Markers. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	255
17	Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. <i>Lancet Oncology</i> , The, 2015, 16, 775-786.	5.1	247
18	Human Papillomavirus Infection with Multiple Types: Pattern of Coinfection and Risk of Cervical Disease. <i>Journal of Infectious Diseases</i> , 2011, 203, 910-920.	1.9	245

#	ARTICLE	IF	CITATIONS
19	A Prospective Study of Human Papillomavirus (HPV) Type 16 DNA Detection by Polymerase Chain Reaction and Its Association with Acquisition and Persistence of Other HPV Types. <i>Journal of Infectious Diseases</i> , 2001, 183, 8-15.	1.9	242
20	Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. <i>Lancet, The</i> , 2013, 382, 877-887.	6.3	239
21	A Population-Based Prospective Study of Carcinogenic Human Papillomavirus Variant Lineages, Viral Persistence, and Cervical Neoplasia. <i>Cancer Research</i> , 2010, 70, 3159-3169.	0.4	221
22	HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. <i>Cell</i> , 2017, 170, 1164-1174.e6.	13.5	221
23	Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. <i>Journal of Experimental Medicine</i> , 2005, 201, 1069-1075.	4.2	209
24	Genome-Wide Expression Profiling Reveals EBV-Associated Inhibition of MHC Class I Expression in Nasopharyngeal Carcinoma. <i>Cancer Research</i> , 2006, 66, 7999-8006.	0.4	207
25	Specific Antibody Levels at the Cervix During the Menstrual Cycle of Women Vaccinated With Human Papillomavirus 16 Virus-Like Particles. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1128-1137.	3.0	205
26	Utility of liquid-based cytology for cervical carcinoma screening. <i>Cancer</i> , 1999, 87, 48-55.	2.0	199
27	Evaluation of Risk Factors for Nasopharyngeal Carcinoma in High-Risk Nasopharyngeal Carcinoma Families in Taiwan. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 900-905.	1.1	198
28	Circulating Inflammation Markers and Prospective Risk for Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1871-1880.	3.0	198
29	Association of HLA Class I and II Alleles and Extended Haplotypes With Nasopharyngeal Carcinoma in Taiwan. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1780-1789.	3.0	193
30	The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: A need for reappraisal. <i>Virus Research</i> , 2009, 143, 209-221.	1.1	187
31	Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial. <i>Cancer Prevention Research</i> , 2013, 6, 1242-1250.	0.7	185
32	Etiology of Nasopharyngeal Carcinoma: A Review. <i>Epidemiologic Reviews</i> , 1993, 15, 466-485.	1.3	183
33	Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. <i>Vaccine</i> , 2006, 24, S171-S177.	1.7	183
34	Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 1997, 1, 362-375.	0.6	183
35	CYP2E1 Genetic Polymorphisms and Risk of Nasopharyngeal Carcinoma in Taiwan. <i>Journal of the National Cancer Institute</i> , 1997, 89, 1207-1212.	3.0	178
36	Seroreactivity to Human Papillomavirus (HPV) Types 16, 18, or 31 and Risk of Subsequent HPV Infection. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 324-327.	1.1	177

#	ARTICLE	IF	CITATIONS
37	Genetic predisposition factors and nasopharyngeal carcinoma risk: A review of epidemiological association studies, 2000–2011. <i>Seminars in Cancer Biology</i> , 2012, 22, 107-116.	4.3	173
38	Epstein-Barr Virus (EBV) in Endemic Burkitt's Lymphoma: Molecular Analysis of Primary Tumor Tissue. <i>Blood</i> , 1998, 91, 1373-1381.	0.6	169
39	The Epidemiology of Oral HPV Infection among a Multinational Sample of Healthy Men. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 172-182.	1.1	169
40	Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. <i>Lancet Oncology</i> , The, 2011, 12, 862-870.	5.1	168
41	Cellular Immune Responses to Human Papillomavirus (HPV) 16 L1 in Healthy Volunteers Immunized with Recombinant HPV 16 L1 Virus-Like Particles. <i>Journal of Infectious Diseases</i> , 2003, 188, 327-338.	1.9	159
42	Comparisons of HPV DNA detection by MY09/11 PCR methods. <i>Journal of Medical Virology</i> , 2002, 68, 417-423.	2.5	158
43	Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1653-1662.	3.0	155
44	Chapter 5: Viral and Host Factors in Human Papillomavirus Persistence and Progression. <i>Journal of the National Cancer Institute Monographs</i> , 2003, 2003, 35-40.	0.9	150
45	Risk for High-Grade Cervical Intraepithelial Neoplasia Associated with Variants of Human Papillomavirus Types 16 and 18. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 4-10.	1.1	146
46	Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. <i>Vaccine</i> , 2008, 26, 4795-4808.	1.7	145
47	Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica. <i>Cancer Discovery</i> , 2011, 1, 408-419.	7.7	143
48	Herpes simplex virus type 2: A possible interaction with human papillomavirus types 16/18 in the development of invasive cervical cancer. <i>International Journal of Cancer</i> , 1991, 49, 335-340.	2.3	135
49	High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. <i>International Journal of Cancer</i> , 2007, 121, 2787-2793.	2.3	134
50	Human Papillomavirus Type 16 and 18 Variants: Race-Related Distribution and Persistence. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1045-1052.	3.0	133
51	HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. <i>Vaccine</i> , 2011, 29, 2011-2014.	1.7	130
52	Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix. <i>Cancer Research</i> , 2003, 63, 7215-20.	0.4	127
53	Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. <i>International Journal of Cancer</i> , 2013, 132, 1412-1422.	2.3	123
54	Human papillomavirus infection and the primary and secondary prevention of cervical cancer. <i>Cancer</i> , 2008, 113, 1980-1993.	2.0	121

#	ARTICLE	IF	CITATIONS
55	Elevated antibody titers to Epstein-Barr virus prior to the diagnosis of Epstein-Barr-virus-associated gastric adenocarcinoma. <i>International Journal of Cancer</i> , 1995, 60, 642-644.	2.3	117
56	Cigarette smoking, alcohol consumption and risk of nasopharyngeal carcinoma in Taiwan. <i>Cancer Causes and Control</i> , 1999, 10, 201-207.	0.8	116
57	Dietary exposure to nitrite and nitrosamines and risk of nasopharyngeal carcinoma in Taiwan. , 2000, 86, 603-609.		116
58	Clinical Trial Designs for the Early Clinical Development of Therapeutic Cancer Vaccines. <i>Journal of Clinical Oncology</i> , 2001, 19, 1848-1854.	0.8	113
59	Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. <i>Cancer</i> , 2003, 98, 814-821.	2.0	112
60	Epidemiologic profile, sexual history, pathologic features, and human papillomavirus status of 103 patients with penile carcinoma. <i>World Journal of Urology</i> , 2013, 31, 861-867.	1.2	110
61	Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 212.e1-212.e15.	0.7	108
62	Common Variants in Immune and DNA Repair Genes and Risk for Human Papillomavirus Persistence and Progression to Cervical Cancer. <i>Journal of Infectious Diseases</i> , 2009, 199, 20-30.	1.9	107
63	p53 polymorphism and risk of cervical cancer. <i>Nature</i> , 1998, 396, 531-532.	13.7	105
64	Relationships of Human Papillomavirus Type, Qualitative Viral Load, and Age with Cytologic Abnormality. <i>Cancer Research</i> , 2006, 66, 10112-10119.	0.4	105
65	Defining the genetic susceptibility to cervical neoplasiaâ€”A genome-wide association study. <i>PLoS Genetics</i> , 2017, 13, e1006866.	1.5	105
66	Common Genetic Variants and Risk for HPV Persistence and Progression to Cervical Cancer. <i>PLoS ONE</i> , 2010, 5, e8667.	1.1	104
67	Evidence for single-dose protection by the bivalent HPV vaccineâ€”Review of the Costa Rica HPV vaccine trial and future research studies. <i>Vaccine</i> , 2018, 36, 4774-4782.	1.7	103
68	Non-viral risk factors for nasopharyngeal carcinoma in the philippines: Results from a case-control study. <i>International Journal of Cancer</i> , 1993, 55, 722-727.	2.3	99
69	Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. <i>Cancer</i> , 1997, 81, 89-97.	2.0	99
70	Methylation of Human Papillomavirus Type 16 Genome and Risk of Cervical Precancer in a Costa Rican Population. <i>Journal of the National Cancer Institute</i> , 2012, 104, 556-565.	3.0	99
71	Persistent Human Papillomavirus Infection Is Associated with a Generalized Decrease in Immune Responsiveness in Older Women. <i>Cancer Research</i> , 2006, 66, 11070-11076.	0.4	98
72	Comparison of mRNA and Protein Measures of Cytokines following Vaccination with Human Papillomavirus-16 L1 Virus-like Particles. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 978-981.	1.1	98

#	ARTICLE	IF	CITATIONS
73	A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection. <i>BMC Infectious Diseases</i> , 2012, 12, 33.	1.3	96
74	Age-Related Changes of the Cervix Influence Human Papillomavirus Type Distribution. <i>Cancer Research</i> , 2006, 66, 1218-1224.	0.4	95
75	Human Leukocyte Antigen Class I and II Alleles and Risk of Cervical Neoplasia: Results from a Population-Based Study in Costa Rica. <i>Journal of Infectious Diseases</i> , 2001, 184, 1310-1314.	1.9	94
76	Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. <i>Vaccine</i> , 2014, 32, 5087-5097.	1.7	92
77	Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv302.	3.0	92
78	Evaluation of Multiplexed Cytokine and Inflammation Marker Measurements: a Methodologic Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1902-1911.	1.1	89
79	Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1038-1046.	3.0	89
80	An Updated Natural History Model of Cervical Cancer: Derivation of Model Parameters. <i>American Journal of Epidemiology</i> , 2014, 180, 545-555.	1.6	87
81	Serologic Response to Helicobacter pylori Proteins Associated With Risk of Colorectal Cancer Among Diverse Populations in the United States. <i>Gastroenterology</i> , 2019, 156, 175-186.e2.	0.6	84
82	Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. <i>Gynecologic Oncology</i> , 2014, 135, 297-304.	0.6	83
83	Behavioral/Lifestyle and Immunologic Factors Associated with HPV Infection among Women Older Than 45 Years. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 3044-3054.	1.1	80
84	Assessment of Human Papillomavirus in Lung Tumor Tissue. <i>Journal of the National Cancer Institute</i> , 2011, 103, 501-507.	3.0	80
85	Body Mass Index, Physical Activity, and Serum Markers of Inflammation, Immunity, and Insulin Resistance. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2840-2849.	1.1	79
86	Epstein-Barr Virus Antibodies and the Risk of Associated Malignancies: Review of the Literature. <i>American Journal of Epidemiology</i> , 2014, 180, 687-695.	1.6	79
87	Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2010, 340, c712-c712.	2.4	78
88	Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. <i>Vaccine</i> , 2008, 26, 3608-3616.	1.7	77
89	Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	77
90	Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	77

#	ARTICLE	IF	CITATIONS
91	Comparison of Two PCR-Based Human Papillomavirus Genotyping Methods. <i>Journal of Clinical Microbiology</i> , 2008, 46, 3437-3445.	1.8	75
92	Genes Involved in DNA Repair and Nitrosamine Metabolism and Those Located on Chromosome 14q32 Are Dysregulated in Nasopharyngeal Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2216-2225.	1.1	74
93	Comparison of the SPF 10 -LiPA System to the Hybrid Capture 2 Assay for Detection of Carcinogenic Human Papillomavirus Genotypes among 5,683 Young Women in Guanacaste, Costa Rica. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1447-1454.	1.8	74
94	Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10 000 women in Guanacaste, Costa Rica. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2004, 15, 75-89.	0.6	74
95	Variation of the Killer Cell Immunoglobulin-Like Receptors and HLA-C Genes in Nasopharyngeal Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 2673-2677.	1.1	73
96	A Comparison of Cervical and Vaginal Human Papillomavirus. <i>Sexually Transmitted Diseases</i> , 2007, 34, 849-855.	0.8	73
97	Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern United States. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 188, 657-663.	0.7	72
98	A Population-Based Study of Vaginal Human Papillomavirus Infection in Hysterectomized Women. <i>Journal of Infectious Diseases</i> , 2004, 190, 458-467.	1.9	72
99	Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial. <i>Journal of the National Cancer Institute</i> , 2018, 110, 205-212.	3.0	71
100	Association of oral contraceptive use and human papillomaviruses in invasive cervical cancers. <i>International Journal of Cancer</i> , 1990, 45, 860-864.	2.3	70
101	Active and Passive Smoking and Risk of Nasopharyngeal Carcinoma: A Population-Based Case-Control Study in Southern China. <i>American Journal of Epidemiology</i> , 2017, 185, 1272-1280.	1.6	68
102	Associations between smoking and adenocarcinomas and squamous cell carcinomas of the uterine cervix (United States). <i>Cancer Causes and Control</i> , 2001, 12, 153-161.	0.8	67
103	Human papillomavirus 16 <sc>E</sc>6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence. <i>Cancer</i> , 2017, 123, 4382-4390.	2.0	67
104	Nasopharyngeal carcinoma and genetic polymorphisms of DNA repair enzymes XRCC1 and hOGG1. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 1100-4.	1.1	67
105	Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. <i>Lancet Oncology</i> , The, 2015, 16, e226-e233.	5.1	66
106	Elevated Systemic Levels of Inflammatory Cytokines in Older Women with Persistent Cervical Human Papillomavirus Infection. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1954-1959.	1.1	64
107	A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma. <i>Blood</i> , 2013, 122, 951-957.	0.6	64
108	Chlamydia trachomatis and Risk of Prevalent and Incident Cervical Premalignancy in a Population-Based Cohort. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1794-1804.	3.0	63

#	ARTICLE	IF	CITATIONS
109	HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. <i>Vaccine</i> , 2005, 23, 3555-3564.	1.7	60
110	Comprehensive Analysis of Human Leukocyte Antigen Class I Alleles and Cervical Neoplasia in 3 Epidemiologic Studies. <i>Journal of Infectious Diseases</i> , 2002, 186, 598-605.	1.9	59
111	Second Cancers After Squamous Cell Carcinoma and Adenocarcinoma of the Cervix. <i>Journal of Clinical Oncology</i> , 2009, 27, 967-973.	0.8	59
112	Associations of Coffee Drinking with Systemic Immune and Inflammatory Markers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1052-1060.	1.1	59
113	Prognostic Utility of Anti-EBV Antibody Testing for Defining NPC Risk among Individuals from High-Risk NPC Families. <i>Clinical Cancer Research</i> , 2011, 17, 1906-1914.	3.2	58
114	Epstein-Barr Virus Serology as a Potential Screening Marker for Nasopharyngeal Carcinoma among High-Risk Individuals from Multiplex Families in Taiwan. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1213-1219.	1.1	58
115	A cross-sectional study of changes in markers of immunological effects and lung health due to exposure to multi-walled carbon nanotubes. <i>Nanotoxicology</i> , 2017, 11, 395-404.	1.6	58
116	Cervicography screening for cervical cancer among 8460 women in a high-risk population. <i>American Journal of Obstetrics and Gynecology</i> , 1999, 180, 290-298.	0.7	56
117	Epstein-Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan. <i>International Journal of Cancer</i> , 2004, 111, 117-123.	2.3	56
118	A Competitive Serological Assay Shows Naturally Acquired Immunity to Human Papillomavirus Infections in the Guanacaste Natural History Study. <i>Journal of Infectious Diseases</i> , 2011, 204, 94-102.	1.9	55
119	Human papillomavirus type 16 E7 protein sensitizes cervical keratinocytes to apoptosis and release of interleukin-1 β . <i>Oncogene</i> , 1998, 17, 1195-1205.	2.6	54
120	Human Papillomavirus 16 E6 Antibodies in Individuals without Diagnosed Cancer: A Pooled Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 683-689.	1.1	54
121	Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. <i>Lancet Oncology</i> , 2020, 21, 1643-1652.	5.1	54
122	Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. <i>Virology</i> , 2006, 353, 451-462.	1.1	53
123	Human Papillomavirus Antibodies and Future Risk of Anogenital Cancer: A Nested Case-Control Study in the European Prospective Investigation Into Cancer and Nutrition Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 877-884.	0.8	53
124	Epidemiologic determinants of vaginal pH. <i>American Journal of Obstetrics and Gynecology</i> , 1999, 180, 1060-1066.	0.7	52
125	Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan. <i>Clinical Cancer Research</i> , 2018, 24, 1305-1314.	3.2	52
126	The Natural History of Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia Among Young Women in the Guanacaste Cohort Shortly After Initiation of Sexual Life. <i>Sexually Transmitted Diseases</i> , 2007, 34, 494-502.	0.8	51

#	ARTICLE	IF	CITATIONS
127	Human Papillomavirus Types by Age in Cervical Cancer Precursors: Predominance of Human Papillomavirus 16 in Young Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 863-865.	1.1	51
128	Prevalence of and Risk Factors for Anal Human Papillomavirus Infection Among Young Healthy Women in Costa Rica. <i>Journal of Infectious Diseases</i> , 2012, 206, 1103-1110.	1.9	51
129	Clustering of Multiple Human Papillomavirus Infections in Women From a Population-Based Study in Guanacaste, Costa Rica. <i>Journal of Infectious Diseases</i> , 2011, 204, 385-390.	1.9	50
130	Association of Aflatoxin and Gallbladder Cancer. <i>Gastroenterology</i> , 2017, 153, 488-494.e1.	0.6	49
131	Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix®. <i>Vaccine</i> , 2012, 31, 165-170.	1.7	48
132	Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. <i>International Journal of Cancer</i> , 2017, 140, 600-610.	2.3	48
133	Screening for human papillomavirus-driven oropharyngeal cancer: Considerations for feasibility and strategies for research. <i>Cancer</i> , 2018, 124, 1859-1866.	2.0	48
134	Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cel collection instrument and correlates of immune measures. <i>Journal of Immunological Methods</i> , 1999, 225, 131-143.	0.6	47
135	Long-Term Persistence of Prevalently Detected Human Papillomavirus Infections in the Absence of Detectable Cervical Precancer and Cancer. <i>Journal of Infectious Diseases</i> , 2011, 203, 814-822.	1.9	47
136	Prevalence of and Risk Factors for Oral Human Papillomavirus Among Young Women in Costa Rica. <i>Journal of Infectious Diseases</i> , 2013, 208, 1643-1652.	1.9	47
137	A GWAS Meta-analysis and Replication Study Identifies a Novel Locus within <i>CLPTM1L/TERT</i> Associated with Nasopharyngeal Carcinoma in Individuals of Chinese Ancestry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 188-192.	1.1	45
138	Fixation and cryopreservation of whole blood and isolated mononuclear cells: Influence of different procedures on lymphocyte subset analysis by flow cytometry. <i>Cytometry Part B - Clinical Cytometry</i> , 2005, 63B, 47-55.	0.7	43
139	Pathological characteristics of cervical adenocarcinoma in a multi-center U.S.-based study. <i>Gynecologic Oncology</i> , 2006, 103, 541-546.	0.6	43
140	Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw300.	3.0	43
141	Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels. <i>Journal of Clinical Immunology</i> , 2002, 22, 23-27.	2.0	42
142	Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1030-1037.	3.0	42
143	Integration of Human Papillomavirus Vaccination and Cervical Cancer Screening in Latin America and the Caribbean. <i>Vaccine</i> , 2008, 26, L88-L95.	1.7	40
144	Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods. <i>BMC Infectious Diseases</i> , 2015, 15, 544.	1.3	40

#	ARTICLE	IF	CITATIONS
145	Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. <i>Oral Oncology</i> , 2020, 108, 104736.	0.8	40
146	Correlates of IL-10 and IL-12 concentrations in cervical secretions. <i>Journal of Clinical Immunology</i> , 2003, 23, 175-183.	2.0	39
147	Familial Tendency and Risk of Nasopharyngeal Carcinoma in Taiwan: Effects of Covariates on Risk. <i>American Journal of Epidemiology</i> , 2011, 173, 292-299.	1.6	39
148	HPV16 Seropositivity and Subsequent HPV16 Infection Risk in a Naturally Infected Population: Comparison of Serological Assays. <i>PLoS ONE</i> , 2013, 8, e53067.	1.1	39
149	Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. <i>Molecular and Cellular Probes</i> , 2012, 26, 73-80.	0.9	37
150	Evaluation of Human Leukocyte Antigen-A (HLA-A), Other Non-HLA Markers on Chromosome 6p21 and Risk of Nasopharyngeal Carcinoma. <i>PLoS ONE</i> , 2012, 7, e42767.	1.1	37
151	Human Leukocyte Antigens and Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma: Old Associations Offer New Clues into the Role of Immunity in Infection-Associated Cancers. <i>Frontiers in Oncology</i> , 2013, 3, 299.	1.3	37
152	Single Nucleotide Polymorphisms in the PRDX3 and RPS19 and Risk of HPV Persistence and Cervical Precancer/Cancer. <i>PLoS ONE</i> , 2012, 7, e33619.	1.1	37
153	Distribution of Epstein-Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan. <i>International Journal of Cancer</i> , 2006, 118, 780-784.	2.3	36
154	Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1399-1406.	1.4	35
155	Determinants of seropositivity among HPV-16/18 DNA positive young women. <i>BMC Infectious Diseases</i> , 2010, 10, 238.	1.3	34
156	Contribution of <i>TMC6</i> and <i>TMC8</i> (<i>EVER1</i> and <i>EVER2</i>) variants to cervical cancer susceptibility. <i>International Journal of Cancer</i> , 2012, 130, 349-355.	2.3	34
157	Comparison of Ophthalmic Sponges for Measurements of Immune Markers from Cervical Secretions. <i>Vaccine Journal</i> , 2004, 11, 399-405.	3.2	33
158	Increased plasma levels of adipokines and inflammatory markers in older women with persistent HPV infection. <i>Cytokine</i> , 2011, 53, 282-285.	1.4	33
159	Persistence of Concurrent Infections with Multiple Human Papillomavirus Types: A Population-based Cohort Study. <i>Journal of Infectious Diseases</i> , 2011, 203, 823-827.	1.9	33
160	High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3451-3457.	3.2	33
161	Lowered Risk of Nasopharyngeal Carcinoma and Intake of Plant Vitamin, Fresh Fish, Green Tea and Coffee: A Case-Control Study in Taiwan. <i>PLoS ONE</i> , 2012, 7, e41779.	1.1	33
162	Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. <i>BMJ</i> , The, 2015, 351, h4358.	3.0	32

#	ARTICLE	IF	CITATIONS
163	Whole-Exome Sequencing of Nasopharyngeal Carcinoma Families Reveals Novel Variants Potentially Involved in Nasopharyngeal Carcinoma. <i>Scientific Reports</i> , 2019, 9, 9916.	1.6	32
164	Prospects for a prophylactic HPV vaccine: Rationale and future implications for cervical cancer screening. <i>Diagnostic Cytopathology</i> , 1998, 18, 5-9.	0.5	31
165	A prospective study of immune and inflammation markers and risk of lung cancer among female never smokers in Shanghai. <i>Carcinogenesis</i> , 2017, 38, 1004-1010.	1.3	31
166	Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes. <i>Journal of Hepatology</i> , 2021, 74, 1132-1144.	1.8	30
167	Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment. <i>International Journal of Cancer</i> , 2012, 131, 211-218.	2.3	29
168	Low risk of type-specific carcinogenic HPV re-appearence with subsequent cervical intraepithelial neoplasia grade 2/3. <i>International Journal of Cancer</i> , 2012, 131, 1874-1881.	2.3	29
169	Cytokine and Chemokine Profiles following Vaccination with Human Papillomavirus Type 16 L1 Virus-Like Particles. <i>Vaccine Journal</i> , 2007, 14, 984-989.	3.2	28
170	Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. <i>Vaccine</i> , 2010, 28, 5407-5413.	1.7	28
171	Seroprevalence and Correlates of Human Papillomavirus 16/18 Seropositivity Among Young Women in Costa Rica. <i>Sexually Transmitted Diseases</i> , 2010, 37, 706-714.	0.8	27
172	Impact of Human Papillomavirus Vaccination on Cervical Cytology Screening, Colposcopy, and Treatment. <i>American Journal of Epidemiology</i> , 2013, 178, 752-760.	1.6	26
173	Circulating inflammatory markers and colorectal cancer risk: A prospective case-cohort study in Japan. <i>International Journal of Cancer</i> , 2018, 143, 2767-2776.	2.3	26
174	Evaluation of a Novel PCR-Based Assay for Detection and Identification of <i>Chlamydia trachomatis</i> Serovars in Cervical Specimens. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3986-3991.	1.8	25
175	Factors Associated with Fluctuations in IgA and IgG Levels at the Cervix during the Menstrual Cycle. <i>Journal of Infectious Diseases</i> , 2009, 199, 455-463.	1.9	25
176	Cancer patterns in nasopharyngeal carcinoma multiplex families in Taiwan. <i>International Journal of Cancer</i> , 2009, 124, 1622-1625.	2.3	25
177	Association of inflammatory and other immune markers with gallbladder cancer: Results from two independent case-control studies. <i>Cytokine</i> , 2016, 83, 217-225.	1.4	25
178	Prediagnostic circulating markers of inflammation and risk of oesophageal adenocarcinoma: a study within the National Cancer Institute Cohort Consortium. <i>Gut</i> , 2019, 68, 960-968.	6.1	25
179	Association of human leukocyte antigens with nasopharyngeal carcinoma in high-risk multiplex families in Taiwan. <i>Human Immunology</i> , 2009, 70, 910-914.	1.2	24
180	Direct Comparison of HPV16 Serological Assays Used to Define HPV-Naïve Women in HPV Vaccine Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1547-1554.	1.1	24

#	ARTICLE	IF	CITATIONS
181	Performance of Self-Collected Cervical Samples in Screening for Future Precancer Using Human Papillomavirus DNA Testing. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju400-dju400.	3.0	24
182	Comparison of Antibody Responses to Human Papillomavirus Vaccination as Measured by Three Assays. <i>Frontiers in Oncology</i> , 2014, 3, 328.	1.3	24
183	Common Genetic Variation in <i>TP53</i> and Risk of Human Papillomavirus Persistence and Progression to CIN3/Cancer Revisited. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1631-1637.	1.1	23
184	Human Leukocyte Antigen Class I and II Alleles and Cervical Adenocarcinoma. <i>Frontiers in Oncology</i> , 2014, 4, 119.	1.3	23
185	Association of circulating inflammation proteins and gallstone disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1920-1924.	1.4	23
186	The Association between the Comprehensive Epstein-Barr Virus Serologic Profile and Endemic Burkitt Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 57-62.	1.1	23
187	Gene Expression Patterns Induced by HPV-16 L1 Virus-Like Particles in Leukocytes from Vaccine Recipients. <i>Journal of Immunology</i> , 2009, 182, 1706-1729.	0.4	22
188	Invited Commentary: Circulating Inflammation Markers and Cancer Risk—Implications for Epidemiologic Studies. <i>American Journal of Epidemiology</i> , 2013, 177, 14-19.	1.6	22
189	Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus. <i>BMC Infectious Diseases</i> , 2014, 14, 120.	1.3	22
190	HLA and KIR Associations of Cervical Neoplasia. <i>Journal of Infectious Diseases</i> , 2018, 218, 2006-2015.	1.9	22
191	No association between genetic polymorphisms of CYP1A1, GSTM1, GSTT1, GSTP1, NAT2, and nasopharyngeal carcinoma in Taiwan. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 179-80.	1.1	22
192	Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. , 2011, 2011, .		21
193	Occupational exposure to diesel engine exhaust and alterations in immune/inflammatory markers: a cross-sectional molecular epidemiology study in China. <i>Carcinogenesis</i> , 2017, 38, 1104-1111.	1.3	21
194	CD83 polymorphisms and cervical cancer risk. <i>Gynecologic Oncology</i> , 2009, 114, 319-322.	0.6	20
195	molBV reveals immune landscape of bacterial vaginosis and predicts human papillomavirus infection natural history. <i>Nature Communications</i> , 2022, 13, 233.	5.8	20
196	An Examination of HPV16 Natural Immunity in Men Who Have Sex with Men (MSM) in the HPV in Men (HIM) Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 496-502.	1.1	19
197	Distribution of dysplasia and cancer in the gallbladder: an analysis from a high cancer-risk population. <i>Human Pathology</i> , 2018, 82, 87-94.	1.1	19
198	Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials. <i>Journal of the National Cancer Institute</i> , 2020, 112, 818-828.	3.0	19

#	ARTICLE	IF	CITATIONS
199	Etiology and Prevention of Cervical Adenocarcinomas. <i>Journal of the National Cancer Institute</i> , 2006, 98, 292-293.	3.0	18
200	Epidemiology of Genital Chlamydia trachomatis Infection Among Young Women in Costa Rica. <i>Sexually Transmitted Diseases</i> , 2008, 35, 461-468.	0.8	18
201	Evaluation of the Polyclonal ELISA HPV Serology Assay as a Biomarker for Human Papillomavirus Exposure. <i>Sexually Transmitted Diseases</i> , 2011, 38, 976-982.	0.8	18
202	Switch from cytology-based to human papillomavirus test-based cervical screening: Implications for colposcopy. <i>International Journal of Cancer</i> , 2012, 130, 1879-1887.	2.3	18
203	Evaluation of a multiplex panel of immune-related markers in cervical secretions: A methodologic study. <i>International Journal of Cancer</i> , 2014, 134, 411-425.	2.3	18
204	Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections. <i>Journal of Infectious Diseases</i> , 2016, 213, 939-947.	1.9	18
205	Premature Years of Life Lost Due to Cancer in the United States in 2017. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2591-2598.	1.1	18
206	Racial Differences in <i>Helicobacter pylori</i> CagA Sero-prevalence in a Consortium of Adult Cohorts in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2084-2092.	1.1	18
207	Evaluation of the FTA Carrier Device for Human Papillomavirus Testing in Developing Countries. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3870-3876.	1.8	17
208	Reduced Prevalence of Vulvar HPV16/18 Infection Among Women Who Received the HPV16/18 Bivalent Vaccine: A Nested Analysis Within the Costa Rica Vaccine Trial. <i>Journal of Infectious Diseases</i> , 2014, 210, 1890-1899.	1.9	17
209	Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. <i>Vaccine</i> , 2015, 33, 2141-2151.	1.7	17
210	Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes. <i>Journal of Infectious Diseases</i> , 2019, 220, 1609-1619.	1.9	17
211	DNase treatment following thawing of Cryopreserved PBMC is a procedure suitable for lymphocyte functional studies. <i>Journal of Immunological Methods</i> , 2006, 313, 209-213.	0.6	16
212	Evaluation of Two Types of Sponges Used To Collect Cervical Secretions and Assessment of Antibody Extraction Protocols for Recovery of Neutralizing Anti-Human Papillomavirus Type 16 Antibodies. <i>Vaccine Journal</i> , 2008, 15, 60-64.	3.2	16
213	Impact of freeze-thaw cycles on circulating inflammation marker measurements. <i>Cytokine</i> , 2017, 95, 113-117.	1.4	16
214	Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials. <i>Journal of Infectious Diseases</i> , 2018, 218, 84-94.	1.9	16
215	Genetic Admixture and Population Substructure in Guanacaste Costa Rica. <i>PLoS ONE</i> , 2010, 5, e13336.	1.1	16
216	A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 815-23.	1.1	16

#	ARTICLE	IF	CITATIONS
217	Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer. <i>International Journal of Cancer</i> , 2009, 125, 1649-1656.	2.3	15
218	Circulating Levels of Inflammatory Proteins and Survival in Patients with Gallbladder Cancer. <i>Scientific Reports</i> , 2018, 8, 5671.	1.6	15
219	Evaluation of nasal and nasopharyngeal swab collection for the detection of Epstein-Barr virus in nasopharyngeal carcinoma. <i>Journal of Medical Virology</i> , 2018, 90, 191-195.	2.5	15
220	Evaluation of the antibody response to the EBV proteome in EBV-associated classical Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2020, 147, 608-618.	2.3	15
221	Patterns of Human Leukocyte Antigen Class I and Class II Associations and Cancer. <i>Cancer Research</i> , 2021, 81, 1148-1152.	0.4	15
222	Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial. <i>Vaccine</i> , 2022, 40, 76-88.	1.7	15
223	Invited Commentary: Epstein-Barr Virus-Based Screening for the Early Detection of Nasopharyngeal Carcinoma—A New Frontier. <i>American Journal of Epidemiology</i> , 2013, 177, 251-253.	1.6	14
224	Characterization of ELISA detection of broad-spectrum anti-Epstein-Barr virus antibodies associated with nasopharyngeal carcinoma. <i>Journal of Medical Virology</i> , 2013, 85, 524-529.	2.5	14
225	Effect of Different Human Papillomavirus Serological and DNA Criteria on Vaccine Efficacy Estimates. <i>American Journal of Epidemiology</i> , 2014, 180, 599-607.	1.6	14
226	Circulating immune/inflammation markers in Chinese workers occupationally exposed to formaldehyde. <i>Carcinogenesis</i> , 2015, 36, 852-857.	1.3	14
227	Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 825-832.	1.1	14
228	Circulating inflammatory proteins and gallbladder cancer: Potential for risk stratification to improve prioritization for cholecystectomy in high-risk regions. <i>Cancer Epidemiology</i> , 2018, 54, 25-30.	0.8	14
229	T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study. <i>PLoS ONE</i> , 2018, 13, e0178167.	1.1	14
230	Circulating inflammation markers and colorectal adenoma risk. <i>Carcinogenesis</i> , 2019, 40, 765-770.	1.3	14
231	Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: A mediation analysis. <i>Cancer Medicine</i> , 2020, 9, 1867-1876.	1.3	14
232	Validation of an Epstein-Barr Virus Antibody Risk Stratification Signature for Nasopharyngeal Carcinoma by Use of Multiplex Serology. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	14
233	Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virus- and hepatitis C virus-infected individuals. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 833-842.	1.9	14
234	Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium. <i>Journal of Clinical Oncology</i> , 2022, 40, 3613-3622.	0.8	14

#	ARTICLE	IF	CITATIONS
235	The von Hippel-Lindau (VHL) disease tumor-suppressor gene is not mutated in nasopharyngeal carcinomas. <i>International Journal of Cancer</i> , 1995, 61, 437-438.	2.3	13
236	Patterns of Interindividual Variability in the Antibody Repertoire Targeting Proteins Across the Epstein-Barr Virus Proteome. <i>Journal of Infectious Diseases</i> , 2018, 217, 1923-1931.	1.9	13
237	Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines. <i>Vaccine</i> , 2006, 24, S227-S232.	1.7	12
238	A Bayesian method for risk window estimation with application to HPV vaccine trial. <i>Computational Statistics and Data Analysis</i> , 2017, 112, 53-62.	0.7	12
239	Design and statistical considerations for studies evaluating the efficacy of a single dose of the human papillomavirus (HPV) vaccine. <i>Contemporary Clinical Trials</i> , 2018, 68, 35-44.	0.8	12
240	Lack of heterogeneity of HPV16 E7 sequence compared with HPV31 and HPV73 may be related to its unique carcinogenic properties. <i>Archives of Virology</i> , 2010, 155, 367-370.	0.9	11
241	Establishment and Operation of a Biorepository for Molecular Epidemiologic Studies in Costa Rica. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 916-922.	1.1	11
242	Application of multiplex arrays for cytokine and chemokine profiling of bile. <i>Cytokine</i> , 2015, 73, 84-90.	1.4	11
243	Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines. <i>Vaccine</i> , 2020, 38, 5997-6006.	1.7	11
244	Partial Least Square Discriminant Analysis Discovered a Dietary Pattern Inversely Associated with Nasopharyngeal Carcinoma Risk. <i>PLoS ONE</i> , 2016, 11, e0155892.	1.1	11
245	Determinants and Correlation of Systemic and Cervical Concentrations of Total IgA and IgG. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2672-2676.	1.1	10
246	Lipopolysaccharide-pathway proteins are associated with gallbladder cancer among adults in Shanghai, China with mediation by systemic inflammation. <i>Annals of Epidemiology</i> , 2016, 26, 704-709.	0.9	10
247	Cervical cancer incidence after screening with HPV, cytology, and visual methods: 18-year follow-up of the Guanacaste cohort. <i>International Journal of Cancer</i> , 2017, 140, 1926-1934.	2.3	10
248	Trends in cervical cancer incidence in younger US women from 2000 to 2013. <i>Gynecologic Oncology</i> , 2017, 144, 391-395.	0.6	10
249	The Natural History of Oral Human Papillomavirus in Young Costa Rican Women. <i>Sexually Transmitted Diseases</i> , 2017, 44, 442-449.	0.8	10
250	A Prospective Study of Circulating Chemokines and Angiogenesis Markers and Risk of Multiple Myeloma and Its Precursor. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz104.	1.4	10
251	Simultaneous measurement of several cytokines using small volumes of biospecimens. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002, 11, 1477-84.	1.1	10
252	HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2016, 2, 141-144.	4.5	9

#	ARTICLE	IF	CITATIONS
253	Circulating inflammation-related markers and advanced gastric premalignant lesions. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 852-856.	1.4	9
254	Prospective assessment of a nasopharyngeal carcinoma risk score in a population undergoing screening. <i>International Journal of Cancer</i> , 2021, 148, 2398-2406.	2.3	9
255	Comparison of new magnetic resonance imaging grading system with conventional endoscopy for the early detection of nasopharyngeal carcinoma. <i>Cancer</i> , 2021, 127, 3403-3412.	2.0	9
256	Oral Immunoglobulin Levels are Not a Good Surrogate for Cervical Immunoglobulin Levels. <i>Frontiers in Oncology</i> , 2012, 2, 61.	1.3	8
257	Industrial hog farming is associated with altered circulating immunological markers. <i>Occupational and Environmental Medicine</i> , 2018, 75, 212-217.	1.3	8
258	Multilaboratory Assessment of Epstein-Barr Virus Serologic Assays: the Case for Standardization. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	8
259	Reproducibility, Temporal Variability, and Concordance of Serum and Fecal Bile Acids and Short Chain Fatty Acids in a Population-Based Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1875-1883.	1.1	8
260	Alterations of T-cell surface markers in older women with persistent human papillomavirus infection. <i>International Journal of Cancer</i> , 2011, 128, 597-607.	2.3	7
261	A prospective study of absolute risk and determinants of human papillomavirus incidence among young women in Costa Rica. <i>BMC Infectious Diseases</i> , 2013, 13, 308.	1.3	7
262	Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2965-2974.	1.4	7
263	Associations between self-reported diabetes and 78 circulating markers of inflammation, immunity, and metabolism among adults in the United States. <i>PLoS ONE</i> , 2017, 12, e0182359.	1.1	7
264	Evaluation of Total and IgA-Specific Antibody Targeting Epstein-Barr Virus Glycoprotein 350 and Nasopharyngeal Carcinoma Risk. <i>Journal of Infectious Diseases</i> , 2018, 218, 886-891.	1.9	7
265	Circulating sCD27 and sCD30 in pre-diagnostic samples collected fifteen years apart and future non-Hodgkin lymphoma risk. <i>International Journal of Cancer</i> , 2019, 144, 1780-1785.	2.3	7
266	Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma. <i>MSphere</i> , 2020, 5, .	1.3	7
267	Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study. <i>Journal of Infectious Diseases</i> , 2021, 223, 1576-1581.	1.9	7
268	HLA Zygosity Increases Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Journal of Infectious Diseases</i> , 2021, , .	1.9	7
269	Utility of Epstein-Barr Virus DNA in Nasopharynx Swabs as a Reflex Test to Triage Seropositive Individuals in Nasopharyngeal Carcinoma Screening Programs. <i>Clinical Chemistry</i> , 2022, 68, 953-962.	1.5	7
270	Inflammatory profiles in Chilean Mapuche and non-Mapuche women with gallstones at risk of developing gallbladder cancer. <i>Scientific Reports</i> , 2021, 11, 3686.	1.6	6

#	ARTICLE	IF	CITATIONS
271	Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. <i>Cancer</i> , 1997, 81, 89-97.	2.0	6
272	HPV vaccination in women aged 24–45 years. <i>Lancet</i> , The, 2009, 374, 1239.	6.3	5
273	Longitudinal Analysis of Carcinogenic Human Papillomavirus Infection and Associated Cytologic Abnormalities in the Guanacaste Natural History Study: Looking Ahead to Cotesting. <i>Journal of Infectious Diseases</i> , 2012, 205, 498-505.	1.9	5
274	Number of Human Papillomavirus Vaccine Doses and Condyloma. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2439.	3.8	5
275	Beasley's 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention. <i>Cancer Epidemiology</i> , 2018, 53, 195-199.	0.8	5
276	Human Papillomavirus Vaccines. , 2018, , 430-455.e10.		5
277	Evaluation of Rare and Common Variants from Suspected Familial or Sporadic Nasopharyngeal Carcinoma (NPC) Susceptibility Genes in Sporadic NPC. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1682-1686.	1.1	5
278	Association Between Common Vaginal Infections and Cervical Non-Human Papillomavirus (HPV) 16/18 Infection in HPV-Vaccinated Women. <i>Journal of Infectious Diseases</i> , 2021, 223, 445-451.	1.9	5
279	Epstein-Barr Virus-Based Nasopharyngeal Carcinoma (NPC) Risk Prediction Scores Are Elevated in NPC Multiplex Family Members in Taiwan. <i>Journal of Infectious Diseases</i> , 2021, 223, 441-444.	1.9	5
280	Association between immunologic markers and cirrhosis in individuals with chronic hepatitis B. <i>Scientific Reports</i> , 2021, 11, 21194.	1.6	5
281	Using Immune Marker Panels to Evaluate the Role of Inflammation in Cancer: Summary of an NCI-Sponsored Workshop. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1427-1433.	1.1	4
282	Household coal combustion, indoor air pollutants, and circulating immunologic/inflammatory markers in rural China. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2019, 82, 411-421.	1.1	4
283	Prediagnostic serum sCD27 and sCD30 in serial samples and risks of non-Hodgkin lymphoma subtypes. <i>International Journal of Cancer</i> , 2020, 146, 3312-3319.	2.3	4
284	Risk Factors for Non-Human Papillomavirus (HPV) Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA-Negative Women Vaccinated Against HPV-16/18 in the Costa Rica Vaccine Trial. <i>Journal of Infectious Diseases</i> , 2021, 224, 503-516.	1.9	4
285	Human leukocyte antigen class I alleles and cervical neoplasia: no heterozygote advantage. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002, 11, 419-20.	1.1	4
286	Characterization of the humoral immune response to the EBV proteome in extranodal NK/T-cell lymphoma. <i>Scientific Reports</i> , 2021, 11, 23664.	1.6	4
287	Reply to P.E. Castle. <i>Journal of Clinical Oncology</i> , 2014, 32, 361-362.	0.8	3
288	0282... A cross-sectional study of markers of early immunological and cardiovascular health effects among a population exposed to carbon nanotubes: the CANTES study 0282... A cross-sectional study of markers of early immunological and cardiovascular health effects among a population exposed to carbon nanotubes: the CANTES study. <i>Occupational and Environmental Medicine</i> , 2014, 71, A35.2-A35.	1.3	3

#	ARTICLE	IF	CITATIONS
289	Association Between Human Leukocyte Antigen Class I and II Diversity and Non-virus-associated Solid Tumors. <i>Frontiers in Genetics</i> , 2021, 12, 675860.	1.1	3
290	Elevated antibodies against Epstein-Barr virus among individuals predicted to carry nasopharyngeal carcinoma susceptibility variants. <i>Journal of General Virology</i> , 2018, 99, 1268-1273.	1.3	3
291	Cancer patterns in nasopharyngeal carcinoma multiplex families over 15 years. <i>Cancer</i> , 2021, 127, 4171-4176.	2.0	2
292	Response to "Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of ASO4 adjuvanted vaccines" by Verstraeten et al.. <i>Vaccine</i> , 2009, 27, 2529.	1.7	1
293	Improved genetic association tests for an ordinal outcome representing the disease progression process. <i>Genetic Epidemiology</i> , 2011, 35, n/a-n/a.	0.6	1
294	Birth order and risk of nasopharyngeal carcinoma in multiplex families from Taiwan. <i>International Journal of Cancer</i> , 2016, 139, 2467-2473.	2.3	1
295	Soluble cluster of differentiation 14 levels elevated in bile from gallbladder cancer cases from Shanghai, China. <i>Scientific Reports</i> , 2021, 11, 13405.	1.6	1
296	HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial. <i>Npj Vaccines</i> , 2022, 7, 40.	2.9	1
297	Reply to P.A. Leppä. <i>Journal of Clinical Oncology</i> , 2009, 27, 3066-3067.	0.8	0
298	Longitudinal Study of Human Papillomavirus Persistence and Cervical Intraepithelial Neoplasia Grade 2/3: Critical Role of Duration of Infection. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 374-376.	0.2	0
299	0442...Elucidating mechanisms using comparative molecular epidemiology: Immunologic alterations in workers exposed to trichloroethylene and formaldehyde. <i>Occupational and Environmental Medicine</i> , 2014, 71, A125-A125.	1.3	0
300	Fewer than three doses of HPV vaccine " Authors' reply. <i>Lancet Oncology</i> , The, 2015, 16, e424-e425.	5.1	0
301	O41-4...Altered circulating immune and inflammation markers among hog farmers in the study of biomarkers of exposure and effect in agriculture. , 2016, , .		0
302	O18-5...Occupational exposure to diesel exhaust and alterations in immune/inflammatory markers. , 2016, , .		0
303	O08-2...Occupational exposure to benzene and alterations in immune/inflammatory markers. , 2016, , .		0
304	FIVE AUTHORS REPLY. <i>American Journal of Epidemiology</i> , 2018, 187, 399-399.	1.6	0
305	Abstract 4824: Little evidence of human papillomavirus in lung tumor tissue. , 2010, , .		0
306	Abstract 5073: Serum sCD23 and sCD30 associated with non-Hodgkin lymphoma risk as far as 15 to 23 years after blood collection. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
307	Abstract 2920: Circulating inflammation markers and subsequent lung cancer risk: A discovery and replication study. , 2014, , .		0
308	Identifying Epstein-Barr virus peptide sequences associated with differential IgG antibody response. International Journal of Infectious Diseases, 2021, 114, 65-71.	1.5	0
309	Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial. Sexually Transmitted Infections, 0, , sextrans-2022-055434.	0.8	0